Showing results (1-10 of 292) with videos related to
Sort By:
Pageof 30
Current Opinion in Rheumatology|January 1, 1994
Rheumatic manifestations of malignancyP G Conaghan, P M BrooksBritish Journal of Rheumatology|April 1, 1997
Anti-rheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994P G Conaghan, M Crotty, E Oh, et al.British Journal of Rheumatology|April 1, 1997
Are rheumatoid arthritis patients more willing to accept non-steroidal anti-inflammatory drug treatment risks than osteoarthritis patients?E Bagge, M Traub, M Crotty, et al.British Journal of Sports Medicine|September 28, 2002
Update on osteoarthritis part 1: current concepts and the relation to exerciseP G ConaghanAnnals of the Rheumatic Diseases|December 16, 1998
Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synoviumO S Jamal, P G Conaghan, A M Cunningham, et al.Current Opinion in Rheumatology|May 1, 1996
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamineP G Conaghan, P BrooksCurrent Opinion in Rheumatology|May 1, 1993
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamineP G Conaghan, P BrooksCurrent Opinion in Rheumatology|May 1, 1995
Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamineP G Conaghan, P BrooksScandinavian Journal of Rheumatology|August 29, 2025
Understanding the use of thermography and its ability to predict ultrasound-detected joint inflammation at the metacarpophalangeal joint in patients with rheumatoid arthritisY K Tan, P G ConaghanDrug Safety|October 1, 1994
Risks and benefits of drugs used in the management and prevention of goutP G Conaghan, R O DayPageof 30